Pernix Therapeutics announces launch of authorized generic version of Treximet®
Pernix announced the launch of an authorized generic version of Treximet® (sumatriptan/naproxen sodium) in the U.S. by the Company’s subsidiary, Macoven Pharmaceuticals. Treximet is a prescription medicine that is indicated for treatment of acute migraine headaches with or without aura. February 16, 2018